Personalised medicine, implementation of the Australian Cancer Plan and expansion of Teletrials are just some of the factors predicted to further shape oncology in 2024.
The limbic gathered the perspectives of a number of medical oncologists on the drivers of practice change and improved outcomes for patients in the near future.
MOGA chair Associate Professor Melissa Eastgate told the limbic that personalised medicine was coming to the forefront of cancer treatment.
“The funding of the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program is a great step forward for our patients so they have access to comprehensive genomic profiling of their tumours which will enable increased access to targeted treatments and clinical trials for patients across Australia,” she said.
Associate Professor Eastgate, Operations Director – Cancer Care Services at the Royal Brisbane and Women’s Hospital, also welcomed the comprehensive Australian Cancer Plan which has been designed to improve cancer outcomes for all Australians.
“2024 will see the beginning of the implementation of the plan, which not only talks about how we can do better for our patients, but also about how we value and support our workforce who are under increasing pressure due to the rising number of patients, the increasing complexity of care and looming workforce shortages.”
Decentralising care
Professor Sabe Sabesan, clinical director of the Queensland Regional Clinical Trial Coordinating Centre in Townsville, is looking forward to a near future in which teletrials become routine practice and improve clinical trial access to all cancer patients.
He says it’s an area in which Australia is already a global leader and that several trial groups and pharmaceutical companies have also adopted the model as part of their health equity agenda.
“For the first time, all states and territories have set up the regional clinical trial coordinating centres and trial support units to embed the Teletrial model as a way of enhancing regional and rural access to clinical trials,” he said.
As well, in many states and territories, Teletrial clusters have been set up for trials involving oral and intravenous therapies.
The TARGET-TP trial, conducted in Melbourne and at four regional centres across Victoria, has demonstrated the efficacy of risk-directed thromboprophylaxis to reduced thromboembolism in patients with lung and GI cancers. [link here]
The trial has also demonstrated financial benefits for patients from a networked teletrial model compared to traveling to a metropolitan centre [link here].
Professor Sabesan also highlighted the MOST-CIRCUIT trial of combination immunotherapy in immunotherapy-sensitive advanced rare cancers.
“The MOST-CIRCUIT trial has enabled two patients from Cairns to enrol locally with Townsville as the primary site. This not only provided patient benefits; but also enhanced collaboration between cancer centres,” he said.
“Based on the success of this COSA-initiated model of care, ASCO has included the COSA model in their telehealth guidelines and the Canadian cancer trial unit has incorporated it into their Remote Access Framework for clinical Trials (CRAFT) and activated three trials using this model. New Zealand has funding to activate the model and trans-Tasman clusters may be a reality.”
“Leveraging the Australian Teletrial Program and the NSW/ACT RRR program, the Australian clinical trial sector has an opportunity to finalise and implement rapid approval processes to create a workforce-enabling and truly patient-centred clinical trial system in Australia.
He said trial groups and pharma have the opportunity to incorporate Teletrial model as a formal recruitment mechanism within their protocols themselves to speed up the health equity agenda.
Paediatrics